Overview

Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease

Status:
Unknown status

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmonary disease.

Phase:

Phase 4

Details

Lead Sponsor:

The First Affiliated Hospital of Guangzhou Medical University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Caspofungin
Echinocandins